Post by
MrMugsy on Sep 05, 2022 9:09am
Indomethacin (ATB-344)
As we sit and wonder what's coming in the new antiviral that has been accepted at the European Patent Office, one only needs to look at trials where Indomethacin and Naproxen as used in COVID trials (without H2S). This might give us an idea of what to expect (then add the H2S boost).
The results in combination with Ketotifen showed an impressive reduction in viral yield - with lower concentrations of Indomethacin beating out the effects of Naproxen (from what I'm seeing - anyway). Can't wait to see what effects an H2S version of Indomethacin might bring (with/without Ketotifen).
"The current findings show that the combination of ketotifen with indomethacin (SJP-002C) or naproxen both significantly reduces viral yield. Compared to ketotifen alone, the combination with indomethacin or naproxen has an additive or synergistic effect. No cytotoxic effects were observed for concentrations of ketotifen, naproxen, and indomethacin tested."
----------------
Wait ... there's more.
Then I found a study that looked at the combination of Indomethacin with a bacterial agent (Ciprofoxacin).
"The combination of ciprofloxacin and indomethacin suppressed the levels of inflammatory cytokines secreted by macrophages in vitro. This study illustrates the regulatory mechanism of drug combinations on innate immune cells that cause inflammatory reactions. In addition, it provides a new potential antibacterial and anti-inflammatory treatment pattern to prevent and cure various complications in the future."
-------------------
Wait a minute ... is this the potential category of "Rare Diseases" that we see on the develoipment wheel?
Maybe with such a platform that 344 represents, can we go after Ebola on the viral side while we chase Pnemonia on the bacterial side. What about parasites like maleria? Are we in play as a combinatorial ?
Can't wait to see where ATB-344 might take us. Interesting.
-------------------
Just thinking out loud - real loud.
: )